Previously, we showed that the PI3K inhibitor/trastuzumab combination therapy is effective against anti-HER2 resistant breast cancer cells bearing PIK3CA mutations and/or losing PTEN expression by the synergistic blockage of downstream signaling and inducing apoptosis in cultivated cells and a xenograft mouse model [15]. This evidence concerns the gene ERBB2 and breast carcinoma.